FDA Wins Abilify Exclusivity Battle; Court Rejects Otsuka's 'Legal Equivalence'

Otsuka claimed Alkermes' Aristada is 'legally equivalent' to Abilify but DC Circuit deferred to FDA's finding that the two have different active moieties and thus Abilify's three-year exclusivity does not apply to Aristada.